Filing Flows › Rigel Pharmaceuticals (RIGL) › Q1 2025
Rigel Pharmaceuticals (RIGL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Rigel Pharmaceuticals (RIGL) reported revenue of $53.3M for the first quarter 2025 (Q1 2025), +81% from a year earlier and -7% from the quarter before. Operating margin was 23.9%, net earnings $11.4M (21.5% of revenue).
Rigel Pharmaceuticals, Q1 2025: revenue $53.3M (+81% year over year), operating margin 23.9%, net earnings $11.4M, operating cash flow −$893K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $53.3M | -7% | +81% |
| Operating profit | $12.8M | -23% | — |
| Net earnings | $11.4M | -20% | — |
| Operating cash flow | −$893K | — | — |
What changed
Revenue was $53.3M in Q1 2025, up 81% year over year and down 7% from the previous quarter. Product sales, net was the largest line at 82% of revenue. Product sales, net added $17.5M year over year (up 67%), 74% of the total change.
Operating profit was $12.8M, a 23.9% margin (up 47.5 points year over year). Total costs grew 11% against revenue growth of 81%. The fastest-growing cost line was Cost of revenue (+118%). Net earnings were $11.4M. The effective tax rate was 0.6%.
Operating cash flow was −$893K. Non-cash charges added back $604K of depreciation and amortization and $3.3M of share-based compensation. Working capital and other items used $16.3M.
Questions
What was Rigel Pharmaceuticals' revenue in the first quarter 2025?
Rigel Pharmaceuticals (RIGL) reported revenue of $53.3M for the first quarter 2025 (Q1 2025), +81% from a year earlier and -7% from the quarter before.
Was Rigel Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $12.8M (23.9% of revenue) and net earnings $11.4M.